Desert Horizons, a California-based cannabis cultivation company, is leading the way in the white-label model, partnering with established brands to produce high-quality cannabis. Their focus on genetics, operational efficiency, and a dedicated team has allowed them to thrive in a competitive market.
Ohio’s adult-use cannabis market is experiencing a surge in sales, with dispensaries reporting strong demand since legalization. However, the economic boom has also raised concerns about road safety, prompting lawmakers to consider new testing measures. While research suggests a potential disconnect between THC levels and driving impairment, the debate over safety measures continues.
Two recent studies highlight the potential benefits of cannabis and CBD in managing symptoms for patients with endometriosis and daytime fatigue. One study found that cannabis was effective in reducing pain and improving sleep quality for endometriosis patients, while another study showed that CBD reduced daytime fatigue and improved psychological well-being.
PharmaCann, a leading cannabis company, has partnered with Mission [Green] Alliance to support federal cannabis reform efforts. This partnership signifies a commitment to social change within the cannabis industry, aiming to provide relief to those unjustly incarcerated for cannabis-related offenses. PharmaCann’s recent $250,000 donation to Mission [Green] Alliance marks a significant step in achieving this goal.
Curio Wellness, a Maryland cannabis company, was fined $8,000 for advertising at a music festival and sponsoring a 5K race, both of which were not age-restricted, violating state regulations. This is not the first time Curio Wellness has been fined for violating cannabis regulations in Maryland. Earlier this year, the company was fined $26,000 for selling marijuana products that had been retrieved from a dumpster by employees.
Former President Donald Trump’s recent support for cannabis legalization in Florida has sent ripples through the cannabis market, causing a mixed reaction among cannabis stocks. While some companies saw gains, reflecting optimism about potential federal changes, others experienced significant drops. This comes as Florida prepares for a November vote on a recreational cannabis initiative, which could significantly impact the industry.
A state audit has revealed significant mismanagement of a $100 million grant program designed to streamline cannabis business licensing in California. The program, established in 2021, has faced criticism for its slow progress and inefficient use of funds. With the program set to expire in 2025, concerns are mounting about its ability to achieve its intended goals.
Aelis Farma’s Phase 2B clinical trial for AEF0117, a potential treatment for cannabis use disorder, did not meet its primary endpoint of reducing cannabis use to one day or less per week. Indivior, which had an option to license the global rights to AEF0117, has decided not to exercise its option due to the lack of separation from placebo in the trial results.
A recent study has challenged the long-held belief that CBD mitigates the effects of THC. Researchers found that high doses of CBD actually enhance the psychotropic effects of THC by increasing its levels in the bloodstream. This discovery has significant implications for the use of CBD-rich cannabis products.
Hollywood icon Jim Belushi, known for his acting career, will headline the Benzinga Cannabis Capital Conference on October 8-9, 2024 in Chicago. The event will feature Belushi’s journey from entertainment to cannabis cultivation, along with insights into his farm and advocacy. This conference offers a unique platform for industry leaders, investors, and entrepreneurs to network and explore the latest advancements in cannabis.
